A new multi-million Euro initiative funded by the European Commission has been set up to help prevent stroke in patients with existing conditions.

The €6.9m project is aimed at patients with atrial fibrillation (AF)—a common heart condition that causes irregular and abnormally fast heartbeat—who have previously had a stroke caused by bleeding in the brain (termed intracerebral hemorrhage, or ICH).

The Prevention of Stroke in intracerebral hemorrhage survivor with Atrial Fibrillation (PRESTIGE-AF) brings together scientists and clinicians across Europe with the goal of reducing the risk of further stroke in this group of patients.

Stroke is one of the largest public health challenges around the world and occurs when the blood supply to the brain is interrupted, such as through a clot or a brain bleed.

It is the most common cause of adult-acquired disability, the second leading cause of death globally, and the second most frequent cause of dementia. In addition, as stroke is a disease of the elderly, its impact is expected to further increase in the coming decades due to the aging population.

At the core of the PRESTIGE-AF project will be a clinical trial to gather evidence around recommended medication for stroke prevention in patients with AF. A number of substudies will explore individual predictive risk modeling using brain imaging, genetic testing, and other biological markers. Other aspects of the project will include exploring cognitive and psychological factors and drug adherence in these patients.

International collaboration

The project will be led by Professor Roland Veltkamp from the Department of Medicine at Imperial College London and involves 11 other partner institutions throughout the UK and across Europe, including Germany, Spain, Italy, Austria, and France. The Consortium members will work collaboratively within the European Commission framework to deliver the desired outcomes over the next 5 years.

Professor Veltkamp said: “Prevention of stroke is challenging in vulnerable stroke patients with multiple disorders and interacting risks. It’s this complexity that makes it difficult to work out the best individual preventive strategy for a particular patient.”

“Working with our international partners through the PRESTIGE-AF initiative, we hope to tackle some of the unmet needs of these patients and develop more personalized treatments. Prevention is key, and ultimately, we aim to prevent stroke and the impact it has on patients’ lives.”